Moderna and Merck's Personalized mRNA Melanoma Vaccine Clears Phase 3, Hits Main Goal

MRNA and MRK said their personalized mRNA cancer vaccine met the primary endpoint of its Phase 3 trial, the first positive late-stage readout for an individualized neoantigen therapy. The INTerpath-001 study tested intismeran autogene, previously known as mRNA-4157, in combination with Merck's KEYTRUDA in patients whose cutaneous melanoma had been completely surgically removed.

The trial enrolled 1,137 patients with resected stage IIB-IV melanoma and randomized them to the vaccine plus KEYTRUDA or to KEYTRUDA alone. It met its primary endpoint of recurrence-free survival and its key secondary endpoint of distant metastasis-free survival, with both improvements described as statistically significant and clinically meaningful and no new safety signals reported.

The mechanism is what makes the result notable. Each dose is built to a specific patient's tumor mutations rather than to a shared target, so a positive Phase 3 validates the whole individualized-neoantigen approach and not just this one product. That matters well beyond melanoma: the same platform is in trials in non-small cell lung cancer and other solid tumors, and a readout of this kind is the gate those programs have been waiting on.

For investors, the read-through differs sharply by company. For Merck the vaccine is an extension of the KEYTRUDA franchise into the adjuvant setting, a way to defend an asset facing loss of exclusivity later this decade. For Moderna it is the clearest evidence to date that its oncology pipeline could carry revenue as COVID-era demand fades, which is a much larger swing factor relative to its size. Watch for the full dataset at a medical meeting, the regulatory filing timeline, and manufacturing commentary, since per-patient bespoke production is the practical constraint on how quickly this could scale.

Related Stocks

• MRK
• MRNA